194 related articles for article (PubMed ID: 12432437)
21. Preference for monthly darbepoetin alfa dosing in patients with chronic kidney disease not receiving dialysis.
Hoggard J; Crouch T; McMurray S; Levine M; Prathikanti R; Scarlata D; Audhya P
Curr Med Res Opin; 2006 Oct; 22(10):2023-30. PubMed ID: 17022861
[TBL] [Abstract][Full Text] [Related]
22. A comparison of haemoglobin levels and doses in haemodialysis patients treated with subcutaneous or intravenous darbepoetin alfa: a German prospective, randomized, multicentre study.
Bommer J; Asmus G; Wenning M; Bommer G
Nephrol Dial Transplant; 2008 Dec; 23(12):4002-8. PubMed ID: 18676350
[TBL] [Abstract][Full Text] [Related]
23. [Treatment of renal anemia with darbepoetin alfa: results of an Austrian multicenter study].
Hörl WH; Holzer H; Mayer GJ;
Wien Klin Wochenschr; 2002 Dec; 114(23-24):967-71. PubMed ID: 12635463
[TBL] [Abstract][Full Text] [Related]
24. Evaluation of the pharmacokinetics of two recombinant human erythropoietin preparations: epoetin zeta and epoetin alfa. 2nd Communication: A monocentric, double-blind, randomized, single dose, three-period crossover trial in healthy volunteers.
Kirkov V; Dimitrova V; Siebert-Weigel M; Wolf-Pflugmann M; Koytchev R; Richter W; Bronn A; Arsova S; Kromminga A
Arzneimittelforschung; 2008; 58(5):220-4. PubMed ID: 18589556
[TBL] [Abstract][Full Text] [Related]
25. An open-label study of darbepoetin alfa administered once monthly for the maintenance of haemoglobin concentrations in patients with chronic kidney disease not receiving dialysis.
Agarwal AK; Silver MR; Reed JE; Dhingra RK; Liu W; Varma N; Stehman-Breen C
J Intern Med; 2006 Dec; 260(6):577-85. PubMed ID: 17116009
[TBL] [Abstract][Full Text] [Related]
26. Darbepoetin alfa administered once monthly maintains haemoglobin levels in stable dialysis patients.
Jadoul M; Vanrenterghem Y; Foret M; Walker R; Gray SJ
Nephrol Dial Transplant; 2004 Apr; 19(4):898-903. PubMed ID: 15031347
[TBL] [Abstract][Full Text] [Related]
27. An overview of the pharmacokinetic disposition of darbepoetin alfa.
Zamboni WC; Stewart CE
Pharmacotherapy; 2002 Sep; 22(9 Pt 2):133S-140S. PubMed ID: 12222583
[TBL] [Abstract][Full Text] [Related]
28. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa.
Glaspy J; Henry D; Patel R; Tchekmedyian S; Applebaum S; Berdeaux D; Lloyd R; Berg R; Austin M; Rossi G;
Eur J Cancer; 2005 May; 41(8):1140-9. PubMed ID: 15911237
[TBL] [Abstract][Full Text] [Related]
29. What is the practical conversion dose when changing from epoetin alfa to darbepoetin outside of clinical trials?
Roger SD; Cooper B
Nephrology (Carlton); 2004 Aug; 9(4):223-8. PubMed ID: 15363054
[TBL] [Abstract][Full Text] [Related]
30. Conversion from epoetin alfa to darbepoetin alfa within the Manitoba Renal Program: evaluation of dose ratios.
Raymond CB; Wazny LD; Vercaigne LM; Lesperance EM; Skwarchuk DE; Bernstein KN
CANNT J; 2008; 18(1):39-43. PubMed ID: 18435363
[TBL] [Abstract][Full Text] [Related]
31. Darbepoetin alfa.
Ibbotson T; Goa KL
Drugs; 2001; 61(14):2097-104; discussion 2105-6. PubMed ID: 11735636
[TBL] [Abstract][Full Text] [Related]
32. Subcutaneous injection pain with C.E.R.A., a continuous erythropoietin receptor activator, compared with darbepoetin alfa.
Pannier A; Jordan P; Dougherty FC; Bour F; Reigner B
Curr Med Res Opin; 2007 Dec; 23(12):3025-32. PubMed ID: 17961301
[TBL] [Abstract][Full Text] [Related]
33. The efficacy of intravenous darbepoetin alfa administered once every 2 weeks in chronic kidney disease patients on haemodialysis.
Carrera F; Oliveira L; Maia P; Mendes T; Ferreira C
Nephrol Dial Transplant; 2006 Oct; 21(10):2846-50. PubMed ID: 16891642
[TBL] [Abstract][Full Text] [Related]
34. Randomized trial to compare the dosage of darbepoetin alfa by administration route in haemodialysis patients.
Kim CD; Park SH; Kim DJ; Park JW; Do JY; Shin SK; Kim BS; Seo JJ; Kim YL
Nephrology (Carlton); 2009 Aug; 14(5):482-7. PubMed ID: 19298639
[TBL] [Abstract][Full Text] [Related]
35. Pharmacokinetics of darbepoetin alfa after single, intravenous or subcutaneous administration in Japanese pediatric patients with chronic kidney disease.
Uemura O; Hattori M; Hataya H; Ito S; Ito N; Akizawa T
Clin Exp Nephrol; 2014 Dec; 18(6):932-8. PubMed ID: 24504705
[TBL] [Abstract][Full Text] [Related]
36. Once-monthly administration of darbepoetin alfa for the treatment of patients with chronic heart failure and anemia: a pharmacokinetic and pharmacodynamic investigation.
Cleland JG; Sullivan JT; Ball S; Horowitz JD; Agoram B; Rosser D; Yates W; Tin L; Fuentealba P; Burton PB
J Cardiovasc Pharmacol; 2005 Aug; 46(2):155-61. PubMed ID: 16044026
[TBL] [Abstract][Full Text] [Related]
37. Effectiveness of weekly darbepoetin alfa in the treatment of anaemia of HIV-infected haemodialysis patients.
Lucas C; Carrera F; Jorge C; Boquinhas H; Pais MJ
Nephrol Dial Transplant; 2006 Nov; 21(11):3202-6. PubMed ID: 16891651
[TBL] [Abstract][Full Text] [Related]
38. Darbepoetin alfa for anemia in chronic kidney disease.
Agarwal AK
Expert Rev Clin Pharmacol; 2008 May; 1(3):369-79. PubMed ID: 24422692
[TBL] [Abstract][Full Text] [Related]
39. [Feasibility strategy of darbepoetin alfa administration every other week: 2005-2007 experience in a dialysis unit].
Rottembourg JB; Dansaert A
Nephrol Ther; 2011 Dec; 7(7):549-57. PubMed ID: 21622039
[TBL] [Abstract][Full Text] [Related]
40. Extended dosing intervals with erythropoiesis-stimulating agents in chronic kidney disease: a review of clinical data.
Carrera F; Disney A; Molina M
Nephrol Dial Transplant; 2007 Jun; 22 Suppl 4():iv19-iv30. PubMed ID: 17526546
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
